PolTREG launches Phase 2 cell therapy trial in children with presymptomatic diabetes
October 24, 2024 01:00 ET
|
PolTREG S.A.
Treating diabetes patients earlier with PTG-007 could provide functional cureRecruitment will go ahead after European Medicines Agency approvalCompany has 12 years’ worth of safety...
PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases
September 26, 2024 01:00 ET
|
PolTREG S.A.
Over a decade of clinical data, experience and know-how with lead polyclonal Treg cell therapy PTG-007 in type-1 diabetes will accelerate CAR-Treg candidate developmentNew CAR-Treg cell therapy...
PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence
September 09, 2024 01:00 ET
|
PolTREG S.A.
PTG-007 cell therapy resulted in clinical remission in some patients for up to 12 yearsA proportion of patients remained insulin-independent for up to 24 monthsPTG-007 ready to enter pivotal studyData...
Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Development
August 01, 2024 09:00 ET
|
Outpace Bio
Seattle, WA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- – Financing syndicate led by RA Capital Management with significant support from a world-class group of existing and new healthcare investors –...
PolTREG appoints Dan Shelly as Chief Business Development Officer
February 21, 2024 01:00 ET
|
PolTREG S.A.
Gdańsk, Poland – 21 February 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune...
PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes
January 16, 2024 01:00 ET
|
PolTREG S.A.
Gdańsk, Poland – 16 January 2024, 07:00 CET – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company in Europe developing cell therapies for use in a wide...
Regenerative Medicine Market Set to Hit USD 194.9 Billion by 2032, Driven by Robust CAGR of 19.4%
January 08, 2024 07:35 ET
|
Market.Us
New York, Jan. 08, 2024 (GLOBE NEWSWIRE) -- According to the market.us, the anticipated value of the Global Regenerative Medicine Market is projected to reach approximately USD 194.9 billion by the...
Cell Therapy Technologies Market to reach USD 36 billion in 2031, expanding at a CAGR of 10.5%: TMR Report
June 19, 2023 10:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, June 19, 2023 (GLOBE NEWSWIRE) -- In 2022, the global cell therapy technologies market was estimated to be worth $14.9 billion USD. It is expected to grow at a...
Outpace Bio to Present New Data on OutSmart™ IL-2/15, a CAR T Cell-Produced Designed Cytokine with Tumor-Localized Immune Cell Activity, at the 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 18, 2023 08:00 ET
|
Outpace Bio
Seattle, WA, May 18, 2023 (GLOBE NEWSWIRE) -- Outpace Bio, a company using protein design and cell engineering to create advanced cell therapies with curative potential, today announced it will...
Outpace Bio, a Leader in Protein Design for Cell Therapy, Announces Presentation at the 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 09, 2023 09:00 ET
|
Outpace Bio
Seattle, WA, May 09, 2023 (GLOBE NEWSWIRE) -- Outpace Bio, a company using protein design and cell engineering to create advanced cell therapies with curative potential, today announced that an...